Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial, but the …
Post
-
-
The clinical trial supply model of the future
Existing clinical trial supply models are facing a number of challenges - increased market competition, growing trial complexity, a significant …
-
EMA posts draft guidance on running trials during public health emergencies
The European Medicines Agency (EMA) has released draft guidance for sponsors conducting clinical trials during public health emergencies (PHEs). The guidance, …
-
DiaMedica gains Health Canada approval for Phase II preeclampsia trial
DiaMedica Therapeutics has received Health Canada clearance for its clinical trial application to begin a Phase II study assessing DM199 …
-
How the AI shift is happening now in data management
The newest generation of AI-driven tools is beginning to reshape how clinical databases are built, governed, and maintained. This is …
-
Seqster unveils 1-Click DataLake for clinical trials
Seqster has launched 1-Click DataLake, a real-world data platform to expedite trial design, recruitment, and evidence generation for healthcare and …
-
Podcast: Sanofi’s head of clinical supply chain operations on evolving the clinical trial supply model
Existing clinical trial supply models are faced with a number of challenges. Increased market competition, growing clinical trial complexity, a …
-
NHS awarded £47.8m to upgrade equipment to improve clinical trials
The UK’s National Health Service (NHS) has been awarded £47.8m ($63.8m) from the National Institute for Health and Care Research …
-
MIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trial
MIRA Pharmaceuticals has completed dosing in its Phase I clinical trial of Ketamir-2, the company’s selective oral N-methyl-D-aspartate (NMDA) receptor …
-
Clinical Trials Arena’s parent company GlobalData moves to Main Market of LSE
LONDON, 05 March 2026 – GlobalData Plc, the trusted intelligence platform and parent company of Clinical Trials Arena, today moves from AIM to the Main Market of …
-
HUTCHMED begins Phase I/IIa trial of HMPL-A580 for solid tumours
HUTCHMED has commenced a Phase I/IIa clinical trial of its second antibody-targeted therapy conjugate (ATTC), HMPL-A580, targeting patients with unresectable, …
-
ArgenX highlights new Vyvgart data, demonstrating early disease control in ocular MG
On 26 February, ArgenX announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the Phase III Adapt …
-
Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure
Theravance Biopharma is restructuring its R&D organisation and cutting its workforce by approximately half after its rare disease blood pressure …
-
Syntis Bio begins patient dosing in Phase I trial of SYNT-101 for obesity
Syntis Bio has dosed the first patient in the SYNTIETY-1 Phase I/Ib trial of SYNT-101, its investigational once-daily oral pill, …
-
Kyowa Kirin discontinues ongoing trials of rocatinlimab
Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody under investigation …
